Skip to main content
. 2012 May 23;75(1):186–196. doi: 10.1111/j.1365-2125.2012.04340.x

Table 1.

Adverse events occurring in three or more subjects

*Preferred term Placebo 0.03 g 0.10 g 0.25 g 0.50 g 1.0 g 2.0 g* 3.0 g All SRT2104
(n = 16) (n = 4) (n = 4) (n = 12) (n = 24) (n = 5) (n = 12) (n = 4) (n = 65)
Headache 1 (6%) 0 1 (25%) 0 8 (33%) 1 (20%) 6 (50%) 2 (50%) 18 (28%)
Flatulence 3 (19%) 2 (50%) 0 0 3 (13%) 2 (40%) 2 (17%) 0 9 (14%)
Infusion site pain 0 0 0 5 (42%) 0 0 0 0 5 (8%)
Nausea 1 (6%) 0 1 (25%) 0 2 (8%) 0 1 (8%) 1 (25%) 5 (8%)
Diarrhoea 0 3 (75%) 0 0 1 (4%) 0 0 0 4 (6%)
Nasopharyngitis 0 0 0 0 2 (8%) 0 1 (8%) 1 (25%) 4 (6%)

MedDRA. Expressed as count (% of total).

*

The only AEs occurring in three or more subjects in the fed state were headaches.

Headache occurred in three subjects in the fasted state and three in the fed state.